Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

NK911 is a novel supramolecular nanocarrier designed for the enhanced delivery of doxorubicin (DXR) and is one of the successful polymer micelle systems to exhibit an efficient accumulation in solid tumours in mice. The purpose of this study was to define the maximum-tolerated dose (MTD) and dose-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumura, Y, Hamaguchi, T, Ura, T, Muro, K, Yamada, Y, Shimada, Y, Shirao, K, Okusaka, T, Ueno, H, Ikeda, M, Watanabe, N
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410050/
https://www.ncbi.nlm.nih.gov/pubmed/15477860
http://dx.doi.org/10.1038/sj.bjc.6602204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410050/
https://www.ncbi.nlm.nih.gov/pubmed/15477860
http://dx.doi.org/10.1038/sj.bjc.6602204

Ejemplares similares